1. OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis. (15th June 2017) Authors: Spiera, R; Hummers, L; Chung, L; Frech, T; Domsic, R; Furst, D; Gordon, J; Mayes, M; Simms, R; Constantine, S; White, B Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. There is a need for new systemic sclerosis subset criteria. A content analytic approach. (2nd January 2018) Authors: Johnson, SR; Soowamber, ML; Fransen, J; Khanna, D; Van Den Hoogen, F; Baron, M; Matucci-Cerinic, M; Denton, CP; Medsger, TA; Carreira, PE; Riemekasten, G; Distler, J; Gabrielli, A; Steen, V; Chung, L; Silver, R; Varga, J; Müller-Ladner, U; Vonk, MC; Walker, UA Journal: Scandinavian journal of rheumatology Issue: Volume 47:Number 1(2018) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗